Medicaid Coverage Tied to Liver Care Gaps

Liver disease programs serving Medicaid-insured patients should track surveillance completion and transplant listing rates by coverage type.

Updated on Nov. 7, 2026 in Healthcare

Flat bold-color editorial illustration of a row of identical vials on a teal surface, with one vial set apart and lit from above.
Four studies presented at The Liver Meeting 2026 found Medicaid coverage linked to lower odds of recommended liver cancer surveillance among patients with cirrhosis. AI Illustration. Upload story photo >

Live Poll

Do you think your health insurance affects the quality of care you receive?

Four studies presented at The Liver Meeting 2026 in Denver found that insurance type and race are linked to disparities in liver disease care. For businesses in healthcare delivery, payer contracting and patient-navigation operations, the findings point to gaps in surveillance follow-up and transplant access tied to coverage status.

Why it matters

The studies suggest that coverage type and education affect whether patients with cirrhosis receive recommended cancer surveillance, and that Medicaid share of transplant listings differs between expansion and nonexpansion states. For operators, that means access gaps are measurable at the program level and may shape how providers and payers design follow-up and outreach.

Surveillance completion was 61.4% annually and 25.9% semiannually among 1,326 cirrhosis patients at four US health systems. Medicaid patients made up 23.6% of 114,778 adult transplant listings in expansion states, compared with 10.0% in nonexpansion states, from 2014 to 2024.

The players

American Association for the Study of Liver Diseases

A professional medical society that organizes The Liver Meeting, the annual gathering for hepatology research and clinical practice.

The details

Researchers enrolled patients with cirrhosis from four US health systems and surveyed them on education, income, insurance, health literacy, housing and barriers to liver care. In that cohort, Medicaid coverage was associated with lower odds of semiannual cancer surveillance (OR 0.55) while a college education was associated with higher odds (OR 1.50). A separate analysis of transplant listings at 142 centers in 33 states found that waitlist mortality was lower among privately insured patients in both expansion and nonexpansion states.

Timeline

  1. 2014: Start of the transplant listing analysis period, a Medicaid expansion year.

  2. 2014-2024: Period covering 114,778 adult liver transplant listings analyzed.

  3. November 5-9, 2026: The Liver Meeting 2026 held in Denver, Colorado.

Market Landscape

The disparities reported fit within the broader expansion-versus-nonexpansion divide in Medicaid coverage that followed the Affordable Care Act. Transplant centers and payers are working within that coverage landscape when planning liver disease follow-up and listing capacity.

Healthcare operators managing hepatology or transplant referral programs should review how surveillance completion and coverage type are tracked in patient panels. Payer contracts and outreach budgets may need to account for the lower follow-up rates documented among Medicaid-insured and less-educated patients.

The takeaway

Track surveillance completion rates by coverage type within liver disease programs as a standing operational metric. Compare those rates against your payer mix before deciding where navigation or outreach resources should go.

Further reading

For broader context on access and coverage across the sector, see Healthcare coverage on We are Main Street.

Live Poll

Do you think your health insurance affects the quality of care you receive?